Boston Scientific begins study of resorbable scaffold technology

Boston Scientific has commenced the Fully Absorbable Scaffold Feasibility Study (FAST), a new clinical trial of its first fully resorbable drug-eluting scaffold system.

The prospective single-arm study will assess the safety and performance of the next-generation scaffold for the treatment of atherosclerotic coronary lesions, with the first patients having already been enrolled at Monash Medical Centre in Melbourne.

Incorporating key design elements from the Boston Scientific Synergy stent system, the scaffold includes a resorbable polymer and ultrathin everolimus coating applied to the scaffold's exterior, plus a high-performance delivery system.

A total of 30 patients will ultimately be enrolled for this study and will be an important milestone in the development of this investigational technology.

Kevin Ballinger, president of interventional cardiology at Boston Scientific, said: "We continue to invest in meaningful innovations designed to provide better outcomes for patients with coronary artery disease."

This comes after the firm began a study last month to assess its Emblem subcutaneous implantable defibrillator system in primary prevention patients with low ejection fraction.